GI Dynamics, Inc. is a medical device company focused on addressing the global diabetes and obesity epidemic. The company operates primarily in the healthcare market, targeting patients with type 2 diabetes and obesity. Their flagship product, EndoBarrier, is a minimally invasive device designed to help manage these conditions by mimicking the effects of gastric bypass surgery without the need for invasive procedures.

EndoBarrier is currently in the investigational stage and is not yet approved for sale in the European Union or the United States. It is limited by Federal US Law to investigational use only. The device works by creating a physical barrier between food and the wall of the intestine, which can lead to improved blood sugar levels and weight loss.

GI Dynamics serves a niche market of patients who are struggling with type 2 diabetes and obesity and are looking for non-surgical treatment options. The company also collaborates with healthcare providers and researchers to conduct clinical trials and gather data on the efficacy and safety of EndoBarrier.

The business model of GI Dynamics revolves around the development, clinical testing, and eventual commercialization of EndoBarrier. They generate revenue through funding from investors and partnerships with healthcare institutions. Once EndoBarrier receives regulatory approval, the company plans to make money by selling the device to healthcare providers and directly to patients.

In summary, GI Dynamics is a healthcare-focused company that aims to provide innovative solutions for managing type 2 diabetes and obesity through its investigational product, EndoBarrier. The company is currently in the clinical trial phase and relies on investor funding and partnerships for its operations.

Keywords: medical device, diabetes, obesity, EndoBarrier, healthcare, clinical trials, non-surgical, investigational, blood sugar, weight loss.